◈ Nootpedia
Compact view
Research pass: thorough Pharmaceutical · Oral OPTIONAL-ADD MEDIUM

Oxiracetam

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OPTIONAL-ADD MEDIUM

Lightest-touch racetam with documented "logical/analytical/energetic" subjective flavor, useful PRN for coding-heavy days, but the most rigorous recent evidence (2023 Korean phase IV n=500, 2024 Frontiers Bayesian meta-analysis) is unimpressive — the encyclopedia's "B-tier vascular dementia" framing leans on 1980s-90s Italian trials that don't replicate at modern methodological standard. Verdict would upgrade to STRONG-CANDIDATE if Dylan runs a clean A/B test and finds it actually delivers the analytical lift; would downgrade to SKIP if it feels equivalent to placebo on his coding throughput.

Research pass: thorough
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    OPTIONAL-ADD PRN

    Useful tool for coding-heavy / analytical days but not a daily driver. Cleaner stim flavor than aniracetam (which has a mood/social slant), lighter than pramiracetam (which is the heavier-focus pick). Stacks safely with V4 (citicoline cofactor already covered) and with V5 modafinil + bromantane (no overlapping mechanism). Daily-safe profile fits Dylan's brief, but the modern evidence (2023 Korean phase IV negative, 2024 meta-analysis MMSE-rank near bottom) doesn't justify daily commitment — PRN A/B test against placebo coding sessions is the right experiment. If oxiracetam clearly delivers an analytical lift on his coding throughput → upgrade to STRONG-CANDIDATE for that use case. If indistinguishable → drop.

  • 30-50, executive maintenance
    OPTIONAL-ADD

    Same logic — pulse on heavy-cognitive days, not daily. Modafinil + caffeine + citicoline covers most of the workspace; oxiracetam is a secondary lever. Renal-clearance profile is favorable (no hepatic burden) for adults with chronic medication loads.

  • 50+, mild cognitive decline (vascular/multi-infarct dementia)
    STRONG-CANDIDATE

    as adjunct, *but* with honest framing — the strongest Italian/Chinese signal is in this population, but the 2023 Korean phase IV failed to replicate and the 2024 Bayesian meta-analysis ranked oxiracetam below butylphthalide, huperzine A, donepezil, edaravone for cognitive endpoints. Use *only after* the better-supported options have been tried, and as part of a multi-agent stack rather than monotherapy. ADL benefit (SUCRA 66) and safety profile (SUCRA 71) are real upsides, so it remains a reasonable choice when the better-supported drugs are contraindicated or unavailable. The (S)-oxiracetam IV preparation has stronger Chinese clinical support for acute stroke / VCI than oral racemate.

  • Anxiety-prone
    SKIP

    as primary tool — oxiracetam's energetic/stim-like flavor can amplify anxiety in susceptible users. Aniracetam is the racetam-family pick for anxious users (anxiolytic on AMPA + 5-HT2A modulation).

  • High athletic load, tested status
    OPTIONAL-ADD

    if untested — oxiracetam is not on WADA's banned list as of the 2026 prohibited list (general nootropic / cognition enhancer, not a stimulant by WADA criteria, no DA mechanism). Compatible with high training volume. For Dylan: no WADA concern (untested status).

  • Sleep-disordered
    CONDITIONAL

    8-hour half-life means PM dosing is a sleep-onset wrecker for late-chronotype users. AM-only dosing (single 800-1600 mg morning load) is the safer protocol. For users with sleep-onset latency >30 min already, oxiracetam can extend it further.

  • Recovery-focused (post-injury, post-illness)
    OPTIONAL-ADD

    Some preclinical signal in cerebral hypoperfusion / TBI models (Akt/mTOR pathway modulation, anti-apoptotic effect on hippocampal neurons) — the (S)-oxiracetam Chinese acute-stroke literature is the strongest signal here. Not first-line for TBI in healthy users; cerebrolysin and citicoline are better-supported for recovery contexts.

  • Strength/anabolic-focused
    NEUTRAL

    No anabolic axis effect, no hormone interaction. Cognitive-only intervention.

▸ Subjective experience (deep)

Onset: 30-60 min for first-day perception; effects accumulate over 3-7 days (similar to other racetams).

Characteristic phenomenology (compiled from Reddit r/Nootropics, Longecity, Braintropic, Nootropics Expert):

  • "Energetic" flavor — most "stim-like" of the classical racetams (sub-phenylpiracetam, but more activating than aniracetam or piracetam). Users describe it as a wakefulness lift without caffeine-style edge.
  • "Logical/analytical thinking" — the dominant descriptor. Reports of improved performance on math, code review, structured writing, multi-step reasoning. Less pronounced effect on creative/divergent tasks (where aniracetam wins).
  • Sustained concentration — duration-of-focus reports are positive; the 8-hour half-life means a single AM dose covers the workday.
  • Mild verbal fluency lift — secondary effect.
  • Reduced "brain fog" in users coming off poor sleep / cognitive fatigue.
  • Insomnia risk if dosed past mid-afternoon — 8-hour half-life = a 2 PM dose is still ~50% concentration at 10 PM. PM dosing is a documented sleep-onset wrecker.
  • Mild headache in ~10-20% of users without choline cofactor — classic racetam side effect.
  • Notable null-response subset (~20-30%) feels nothing distinguishable from placebo, even at 1600 mg/day.

Compared to aniracetam: oxiracetam is more energetic, less anxiolytic, less mood-modulating, longer-lasting (8 hr vs 2-3 hr). Compared to pramiracetam: oxiracetam is lighter, more energetic, less "memory-focused"; pramiracetam is the heavier-hitter for sustained focus + memory consolidation, oxiracetam is the lighter analytical-lift tool. Compared to phenylpiracetam: oxiracetam is much milder, no DA arm, no tolerance issue, daily-safe; phenylpiracetam is intermittent-only because of fast tolerance. Compared to modafinil: oxiracetam is much weaker, no wakefulness drive comparable to a eugeroic — should not be expected to substitute for modafinil's anti-fatigue effect.

▸ Tolerance + cycling deep dive
  • Tolerance buildup: minimal-to-low. Mechanism (AMPA-binding-site density modulation + facilitate-when-active cholinergic) does not deplete neurotransmitter pools or trigger receptor downregulation in available data. Italian 1-year continuous use showed sustained benefit.
  • Recommended cycle for Dylan: PRN-only is the cleanest approach — no need to cycle if used 3-4×/week on coding days. If used daily, conservative approach is 8 weeks on / 2 weeks off for novelty preservation, though the pharmacological case for cycling is weaker than for stim-class compounds.
  • Reset protocol if needed: 2-week washout. Renal clearance is fast (8-hour half-life means 95% gone in 40 hours); the only reason to do a longer reset is subjective novelty, not pharmacological.
▸ Stacking deep dive

Synergistic with

  • citicoline: Mandatory cofactor — Dylan's V4 already includes 500 mg/day Cognizin, which covers the choline demand from oxiracetam-induced ACh release upregulation. Without citicoline (or alpha-GPC), expect the classic racetam headache.
  • alpha-gpc: PRN pre-task booster (300-600 mg) provides faster acute choline elevation than citicoline. Stack with oxiracetam on heavy-load days for maximum cholinergic support.
  • aniracetam: Different mood/anxiolytic flavor, complementary subjective profile. Some users stack 800 mg oxiracetam AM + 750 mg aniracetam later (or vice versa) for "logical + creative" coverage. Same choline cofactor covers both.
  • pramiracetam: Heavier focus/memory partner; oxiracetam-pramiracetam is a classic biohacker stack. Both deplete choline, so increase cofactor accordingly (alpha-GPC 600 mg + citicoline 500 mg).
  • modafinil: Different mechanisms (modafinil = wakefulness/DA; oxiracetam = AMPA/cholinergic). Theoretical complementarity. No published interaction data — empirical reports positive. Time both AM to avoid PM sleep collision.
  • caffeine (Dylan's V4 ramp): Synergistic on focus axis. No documented interaction concerns at moderate caffeine doses.
  • NAC (Dylan's V4): Antioxidant/glutamatergic-modulating; theoretically complementary to oxiracetam's mild glutamate-release effect. No conflicts reported.

Avoid stacking with

  • Other strong AMPA modulators (TAK-653, ampakines): Theoretical additive AMPA potentiation — not characterized but worth caution. Dylan's V5 plan does include TAK-653 watch-list — if both ever run together, start each separately and add carefully.
  • Heavy alcohol (not relevant for Dylan): Some racetam-alcohol interaction reports (additive cognitive impairment despite the racetam being nominally "pro-cognitive").

Neutral / safe co-administration

Magnesium (any form), DHA, phosphatidylserine, beta-alanine, creatine, vitamin D3, vitamin C, curcumin, theanine, rhodiola, glycine, beta-alanine — Dylan's V4 daily core is fully compatible. ALCAR pairing is theoretically complementary (mitochondrial + cholinergic) but not directly studied with oxiracetam.

▸ Drug interactions deep dive
  • CYP enzymes: Minimal hepatic metabolism (~84% excreted unchanged) — no significant CYP induction or inhibition. Low drug-interaction profile via metabolism.
  • Renally-cleared drugs: Theoretical competition at renal tubular secretion sites (oxiracetam shares active secretion with some drug classes), but no clinically documented interactions.
  • Hormonal contraceptives: No interaction expected (no CYP3A4 effect).
  • Antidepressants (SSRIs, SNRIs, tricyclics): No documented interactions.
  • Anticoagulants (warfarin, DOACs): No documented interactions.
  • Anticonvulsants: Theoretical caution given AMPA modulation, though oxiracetam itself shows anti-convulsant activity in animal models.
  • Other nootropics: Stacks cleanly with cholinergics, racetams, eugeroics in available data.
  • Alcohol: Not characterized in modern trials; not relevant for Dylan.
▸ Pharmacogenomics
  • Limited published data. Oxiracetam has minimal CYP involvement, so the standard CYP2D6/CYP3A4 PM/UM stratification is not strongly relevant.
  • Renal SNPs: Genetic variants affecting glomerular filtration rate (e.g., UMOD, SHROOM3) could theoretically alter clearance, but no clinical reports for oxiracetam specifically.
  • AMPA receptor subunit polymorphisms (GRIA1-4): No published differential-response data; theoretical interest. Dylan's 23andMe results (~June 2026) include some GRIA-related SNPs — could be looked at if oxiracetam is run as a formal A/B test.
  • CHAT / CHRNA polymorphisms: Cholinergic genes — theoretical relevance to racetam response. No clinical PGx data.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
Research-chem (US-friendly) Nootropics Depot $22-30 / 60 caps × 750 mg ($0.40/dose) High — independent COA + HPLC, well-known nootropic vendor Powder + capsule formats. Good first stop for US-shipped oxiracetam.
Research-chem Pure Rawz ~$15-25 / 30 g powder Medium-High — third-party tested, COA available US-made claim, capsule + powder. Lower per-gram than NootDepot.
Research-chem Science.bio (when available) Variable Medium-High — historically reliable third-party COA Stock varies; older nootropic-community favorite.
Research-chem SwissChems Lowest per-dose pricing for racetam class, 20% crypto discount, third-party COA Medium — newer-generation vendor, mixed but mostly positive reviews Capsule format common.
Research-chem RCpeptides / RCDBio ~$20-30/mo at 800 mg BID Medium Third-party tested.
EU Rx (gray-import) Italian pharmacies (Neuromet 800 mg cap) Variable + import friction Medium — pharmaceutical-grade but logistically painful The original SmithKline Beecham product, prescription-only in Italy. Generally not worth the import overhead vs. US research-chem.
Avoid Random Amazon / eBay listings Variable Low Oxiracetam on mainstream platforms is suspect; product authenticity unverified.

Sourcing reality 2026: Oxiracetam is well-established on the research-chem circuit, COA-verified product is easy to find, and cost is reasonable at $15-25/mo for an 800 mg BID protocol (3-5×/week PRN use cuts that to ~$10/mo). Top picks for Dylan: (1) Nootropics Depot (highest trust, modest premium), (2) Pure Rawz or SwissChems (cheaper, COA-backed). Capsule format is recommended (no scale required for 800 mg dosing). COA mandatory.

▸ Biomarkers to track (deep)
  • Baseline (before starting): Resting cognitive performance (subjective focus 1-10, optionally Stroop / N-back if formally A/B testing), sleep onset latency, creatinine + eGFR (single most-relevant safety variable for renally-cleared drug), subjective headache baseline. For Dylan: piggyback on June 2026 bloodwork.
  • During use (week 1, week 4, week 8): Sleep onset latency (Ring-Health HRV / wearable), subjective focus / output (1-10 daily on coding days, with placebo days for comparison), headache occurrence (binary log), any change in resting HR or BP. For formal A/B: alternate oxiracetam and placebo capsules across coding sessions, blind to which is which, score session output and subjective focus. Run for 8-12 sessions before drawing conclusions.
  • Post-cycle (if cycled): Subjective focus return-to-baseline within ~3-5 days after stopping (renal clearance fast).
▸ Controversies / open debates Live debate

1. The "B-tier vascular dementia" label is shakier than encyclopedia framing implies. The Italian Catania trials (Maina 1989, Bottini 1992) were positive but small, single-country, 1980s methodology. The 2024 Frontiers Bayesian meta-analysis pooled 27 RCTs (most Chinese) and found oxiracetam ranked near the bottom on MMSE (SUCRA 20.82) — better than placebo but well behind butylphthalide, huperzine A, donepezil, edaravone. The 2023 Korean phase IV (Lim et al., n=500, 36 weeks) was the most rigorous modern trial and was NEGATIVE on co-primary endpoints, leading to South Korean regulatory suspension. Honest verdict-defense: B-tier signal exists but the most rigorous modern trial failed. The encyclopedia statement "B-tier vascular dementia (Italy/EU)" should be qualified — the historical Italian signal is real but doesn't replicate cleanly in modern methodology, and recent regulatory action (South Korea) reflects this.

2. AMPA PAM vs. classical PAM — racetams are weak modulators. Encyclopedia framing of "AMPA + cholinergic + glutamatergic modulation" is technically correct but obscures that racetams (oxiracetam included) are weak AMPA modulators acting at a binding-site density mechanism, not at the canonical aniracetam/CTZ-class PAM site. Compared to true ampakines (CX-516, CX-717) or modern PAMs (TAK-653), racetam AMPA effects are small. This is consistent with the modest clinical effect sizes observed in trials. Not a falsehood, but a context-needed framing.

3. Subjective "logical/analytical thinking" claim is anecdote-only. No published RCT in healthy adults has measured this specific claim with formal analytical-task batteries. The "logical/analytical flavor" descriptor is a Reddit/Longecity/biohacker convention dating back to the early 2000s, originally compared to aniracetam's "creative" flavor. There is no measurement-grade evidence that oxiracetam selectively improves analytical/logical task performance in young, cognitively-intact users. It might; we don't know. A clean A/B coding-session protocol would be the only way to test this for Dylan specifically.

4. (S)-oxiracetam vs. racemic — clinical equivalence question. The (S)-enantiomer is the pharmacologically active form, and Chinese regulatory development has focused on (S)-oxiracetam IV for stroke / VCI. Whether the racemic oral is half-as-good or roughly equivalent in vivo (the inactive (R) being a passive bystander) is debated; published PK data on (S)-oxiracetam alone shows linear PK and clean tolerability but doesn't directly address whether racemic-oral users are getting full or half therapeutic effect. Practical implication: research-chem oxiracetam is racemic. If you wanted maximally efficient dosing you'd want (S)-only, but that's not commercially available outside Chinese pharma.

5. Renal impairment flag — easy to miss. Half-life jumps from 8 hours (healthy young) to 10-68 hours (renal impairment). This is the single largest safety variable for the drug and is rarely emphasized in nootropic-community sources. Not relevant for Dylan barring an unforeseen finding, but worth documenting for the wiki.

6. The Italian Neuromet authorization is real but doesn't generalize. SmithKline Beecham launched Neuromet (oxiracetam 800 mg cap + 1 g/5 mL IV) in Italy in 1987 under SmithKline's domestic marketing. It remains Rx-only in Italy and is listed in China's Drug Catalog. It is not FDA-approved, has never had US clinical-trial development beyond a planned SmithKline Beecham Phase II AD trial that never produced results. The "approved in Italy" framing is true but should not be confused with FDA-grade evidence — Italian and Chinese regulatory paths have been historically friendlier to nootropics than the FDA.

▸ Verdict change log
  • 2026-05-05 — Initial verdict: OPTIONAL-ADD PRN, MEDIUM confidence. Lightest racetam with credible "energetic/analytical" subjective flavor (anecdote-heavy but consistent), favorable safety profile, low cost. Good fit for Dylan as a PRN tool on coding-heavy days, stacked with V4 citicoline + PRN alpha-GPC. Not a daily driver — modern RCT signal is unimpressive (2023 Korean phase IV NEGATIVE; 2024 Bayesian meta-analysis ranks 6th-of-21 with poor MMSE SUCRA), and the "logical thinking" claim is anecdote-only. Run a clean A/B coding-session test (8-12 sessions, oxiracetam vs placebo, scored on subjective focus + session output) before committing further. Would upgrade to STRONG-CANDIDATE if A/B test shows reproducible analytical lift; would downgrade to SKIP-FOR-NOW if indistinguishable from placebo on his work.
▸ Open questions / gaps Open
  1. Why did the 2023 Korean phase IV fail when 1980s Italian trials succeeded? Likely candidates: (a) post-stroke chronic VCI population is harder to move than mild-moderate dementia, (b) modern methodology with larger n exposes effect-size that was overstated in small earlier trials, (c) co-administered statins/antiplatelets/antihypertensives in modern stroke patients alter the target. Honest answer: the 1980s signal was probably real-but-modest, and the modern bar is harder to clear.
  2. Does oxiracetam selectively improve analytical/logical task performance in healthy young adults? No formal trial data. The claim rests on biohacker convention. Worth A/B testing for Dylan.
  3. Is (S)-oxiracetam IV substantively better than racemic oral? Chinese clinical experience suggests yes for acute indications, but no head-to-head trial.
  4. Pharmacogenomics: GRIA subunit SNPs and cholinergic-gene polymorphisms might predict responder/non-responder split — never studied. The ~20-30% null-response rate is real but unexplained.
  5. Long-term (>1 year) cognitive outcomes: Italian 1-year extension is the longest published follow-up. No reason to expect new toxicity; effect sustainment / fade is unmeasured beyond that window.
  6. Interaction with TAK-653 (planned V5 watch-list): Two AMPA modulators stacked — theoretical additive but never characterized. If both are ever run for Dylan, start sequentially.
▸ Sources (full, with our context)
Back to compact view